Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-09-01 DOI:10.1358/mf.2010.32.7.1549223

A Tomillero, M A Moral

{"title":"Gateways to clinical trials.","authors":"A Tomillero, M A Moral","doi":"10.1358/mf.2010.32.7.1549223","DOIUrl":null,"url":null,"abstract":"<p><p>Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placarbil, Aripiprazole, ARQ-621, Azelnidipine, Azilsartan medoxomil potassium; Bevacizumab, Biphasic insulin aspart, Bortezomib; Choriogonadotropin alfa, CTS-1027; Dapagliflozin, Dasatinib, Deforolimus, Degarelix acetate, Denufosol tetrasodium, Desvenlafaxine succinate, Dronedarone hydrochloride, Duloxetine hydrochloride, Dutasteride; Enfuvirtide, Entecavir, Etaracizumab, Everolimus, Exenatide, Ezetimibe; Ferric carboxymaltose, Fludarabine, Foretinib; Gefitinib, GFT-505, GSK-256066; HPV-6/11/16/18, HuM195/rGel, HyperAcute-Lung cancer vaccine; I5NP, Imatinib mesylate, Imexon, Insulin detemir, Insulin glargine, Ivabradine hydrochloride; L2G7, Lacosamide, Lapatinib ditosylate, Lenalidomide, Lidocaine/prilocaine, Liposomal vincristine, Liraglutide, Lixivaptan; Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Methoxy polyethylene glycol-epoetin-β, Mirabegron, Morphine/oxycodone, MR Vaccine, MSC-1936369B, Mycophenolic acid sodium salt; Narlaprevir, N-Desmethylclozapine; Ocriplasmin, Olaparib, Olmesartan medoxomil, Olmesartan medoxomil/azelnidipine, ONO-5334, ONO-8539; Palifermin, Panitumumab, Pardoprunox hydrochloride, PCV7, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pexelizumab, PF-337210, Pitavastatin calcium; Raltegravir potassium, Recombinant interleukin-7, Regadenoson, Reniale, Roflumilast, Rosuvastatin calcium; Safinamide mesilate, SB-1518, SCH-527123, Selumetinib, Sipuleucel-T, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talaporfin sodium, Tanespimycin, Technosphere/Insulin, Telaprevir, Telatinib, Telcagepant, Telmisartan/hydrochlorothiazide, Teriparatide, Testosterone transdermal gel, TH-302, Tiotropium bromide, Tocilizumab, Trabedersen, Tremelimumab; Valsartan/amlodipine besylate, Vernakalant hydrochloride, Visilizumab, Voreloxin, Vorinostat.</p>","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Methods and findings in experimental and clinical pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/mf.2010.32.7.1549223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placarbil, Aripiprazole, ARQ-621, Azelnidipine, Azilsartan medoxomil potassium; Bevacizumab, Biphasic insulin aspart, Bortezomib; Choriogonadotropin alfa, CTS-1027; Dapagliflozin, Dasatinib, Deforolimus, Degarelix acetate, Denufosol tetrasodium, Desvenlafaxine succinate, Dronedarone hydrochloride, Duloxetine hydrochloride, Dutasteride; Enfuvirtide, Entecavir, Etaracizumab, Everolimus, Exenatide, Ezetimibe; Ferric carboxymaltose, Fludarabine, Foretinib; Gefitinib, GFT-505, GSK-256066; HPV-6/11/16/18, HuM195/rGel, HyperAcute-Lung cancer vaccine; I5NP, Imatinib mesylate, Imexon, Insulin detemir, Insulin glargine, Ivabradine hydrochloride; L2G7, Lacosamide, Lapatinib ditosylate, Lenalidomide, Lidocaine/prilocaine, Liposomal vincristine, Liraglutide, Lixivaptan; Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Methoxy polyethylene glycol-epoetin-β, Mirabegron, Morphine/oxycodone, MR Vaccine, MSC-1936369B, Mycophenolic acid sodium salt; Narlaprevir, N-Desmethylclozapine; Ocriplasmin, Olaparib, Olmesartan medoxomil, Olmesartan medoxomil/azelnidipine, ONO-5334, ONO-8539; Palifermin, Panitumumab, Pardoprunox hydrochloride, PCV7, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pexelizumab, PF-337210, Pitavastatin calcium; Raltegravir potassium, Recombinant interleukin-7, Regadenoson, Reniale, Roflumilast, Rosuvastatin calcium; Safinamide mesilate, SB-1518, SCH-527123, Selumetinib, Sipuleucel-T, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talaporfin sodium, Tanespimycin, Technosphere/Insulin, Telaprevir, Telatinib, Telcagepant, Telmisartan/hydrochlorothiazide, Teriparatide, Testosterone transdermal gel, TH-302, Tiotropium bromide, Tocilizumab, Trabedersen, Tremelimumab; Valsartan/amlodipine besylate, Vernakalant hydrochloride, Visilizumab, Voreloxin, Vorinostat.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

通往临床试验的大门。

溴化阿克啶、AE-37、阿仑妥珠单抗、AMA1-C1/ISA 720、苯磺酸氨氯地平/阿托伐他汀钙、Arbaclofen placarbil、阿立哌唑、ARQ-621、阿泽尼地平、阿兹沙坦美多索米钾;贝伐单抗、双相胰岛素分离、硼替佐米;绒毛膜促性腺激素;达格列净、达沙替尼、去福莫司、醋酸德格雷利克斯、癸萘酚四钠、琥珀酸地文拉法辛、盐酸德罗达酮、盐酸度洛西汀、度他雄胺;恩福韦肽、恩替卡韦、依他拉西单抗、依维莫司、艾塞那肽、依折可米;羧麦芽糖铁、氟达拉滨、福替尼;吉非替尼，GFT-505, GSK-256066;HPV-6/11/16/18, HuM195/rGel，超急性肺癌疫苗;I5NP、甲磺酸伊马替尼、依美森、地特米胰岛素、甘精胰岛素、盐酸伊伐布雷定;L2G7:拉科沙胺、二甲磺酸拉帕替尼、来那度胺、利多卡因/普利洛卡因、长春新碱脂质体、利拉鲁肽、利西瓦坦;脑膜炎球菌(A、C、Y和W-135组)低聚糖白喉CRM197结合疫苗，甲氧基聚乙二醇-表生素-β，米拉贝龙，吗啡/羟考酮，MR疫苗，MSC-1936369B，霉酚酸钠盐;Narlaprevir N-Desmethylclozapine;奥克里帕敏、奥拉帕尼、奥美沙坦美多索米、奥美沙坦美多索米/阿泽尼地平、ONO-5334、ONO-8539;Palifermin、帕尼珠单抗、盐酸帕多普诺克斯、PCV7、聚乙二醇干扰素α -2a、聚乙二醇干扰素α -2b、培美曲塞二钠、培利珠单抗、PF-337210、匹伐他汀钙;雷替格拉韦钾、重组白细胞介素-7、瑞腺苷松、瑞尼乐、罗氟司特、瑞舒伐他汀钙;甲磺酸沙非胺、SB-1518、SCH-527123、Selumetinib、Sipuleucel-T、琥珀酸索利那新、索拉非尼、苹果酸舒尼替尼;他达拉非、他拉波芬钠、他那霉素、Technosphere/胰岛素、特拉匹韦、特拉替尼、特拉吉潘、替米沙坦/氢氯噻嗪、特立帕肽、睾酮透皮凝胶、TH-302、噻托溴铵、托珠单抗、Trabedersen、Tremelimumab;缬沙坦/苯磺酸氨氯地平，盐酸维那卡兰特，Visilizumab, Voreloxin, Vorinostat。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Methods and findings in experimental and clinical pharmacology 医学-药学

自引率

0.00%

发文量

审稿时长

>12 weeks